Ads
related to: alternative to ritalin adults medication classification program
Search results
Results From The WOW.Com Content Network
3D molecular rendering of methylphenidate (MPH). This is a list of methylphenidate (MPH or MPD) analogues, or Phenidates.The most well known compound from this family, methylphenidate, is widely prescribed around the world for the treatment of attention deficit hyperactivity disorder (ADHD) and certain other indications.
This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in ...
Methylphenidate, sold under the brand names Ritalin (/ ˈ r ɪ t ə l ɪ n / RIT-ə-lin) and Concerta (/ k ə n ˈ s ɜːr t ə / kən-SUR-tə) [citation needed] among others, is a central nervous system (CNS) stimulant used in the pharmacotherapy of attention deficit hyperactivity disorder (ADHD) and narcolepsy.
Dr. Lenard Adler, director of the adult ADHD program at NYU Langone Medical Center in New York, said about 30% to 40% of the prescriptions he writes for ADHD medications have to be rewritten ...
Initially the drug was used to treat narcolepsy, chronic fatigue, depression, and to counter the sedating effects of other medications. The drug began to be used for ADHD in the 1960s and steadily rose in use. [222] In 1975, pemoline (Cylert) was approved by the U.S. FDA for use in the treatment of ADHD. While an effective agent for managing ...
Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12 years, adolescents age 13 to 17 years, and adults. [1]Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.
U.S. Food and Drug Administration-commissioned studies in 2011 indicate that in children, young adults, and adults, there is no association between serious adverse cardiovascular events (sudden death, heart attack, and stroke) and the medical use of methylphenidate or other ADHD stimulants.
threo-4-Methylmethylphenidate (4-MeTMP) is a stimulant drug related to methylphenidate.It is slightly less potent than methylphenidate and has relatively low efficacy at blocking dopamine reuptake despite its high binding affinity, which led to its investigation as a possible substitute drug for treatment of stimulant abuse (cf. nocaine). [1]